abbvie logo

AbbVie Gets U.S. FDA Priority Review for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for Treating Chronic Hepatitis C

Feb 02, 2017 AbbVie, a global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), being evaluated for treating all major genotypes (GT1-6) of chronic hepatitis C virus (HCV). The FDA grants priority review … Continue reading AbbVie Gets U.S. FDA Priority Review for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for Treating Chronic Hepatitis C

Advertisements
integra-jnj

Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

Feb 15, 2017 Integra Lifesciences, a prominent medical device maker, has announced that it will acquire the Codman Neurosurgery business of Johnson & Johnson's (JNJ) for $1.05 billion. The Codman unit of JNJ includes a portfolio of medical devices focusing on advanced hydrocephalus, operative neurosurgery, and neuro-critical care, according to the company. During 2016, the acquired products generated approximately $370 million … Continue reading Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

seattle-1

Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

February 10, 2017 Seat­tle Ge­net­ics has become the new flag car­rier for the solid tumor drug IMMU-132 of   Im­munomedics. In order to claim global rights on the drug, Seat­tle Ge­net­ics is pay­ing $300 mil­lion, and also com­mit­ting up to $1.7 bil­lion more in mile­stones. The biotech will now take the lead on a Phase III … Continue reading Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

Merck Igea Luca Dezzani

FDA Accepts Two sBLAs for the KEYTRUDA (pembrolizumab) of Merck for Locally Advanced or Metastatic Urothelial Cancer

February 3, 2017 Merck has announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer. In particular, the application for first-line use was accepted and granted … Continue reading FDA Accepts Two sBLAs for the KEYTRUDA (pembrolizumab) of Merck for Locally Advanced or Metastatic Urothelial Cancer

bayer-jj

Bayer and J&J wrap positive PhIII cardio study for Xarelto

February 8, 2017 Bayer and its part­ners at J&J, back in the fall of 2012, started a mas­sive study to see if the drug Xarelto (ri­varox­a­ban) could help pre­vent major car­dio­vas­cu­lar events like my­ocar­dial in­farc­tion, stroke, and death in high risk pa­tients with coro­nary artery dis­ease or pe­riph­eral artery dis­ease. Very recently, a lit­tle more … Continue reading Bayer and J&J wrap positive PhIII cardio study for Xarelto

Novartis logo - luca dezzani

Novartis drug Votubia® receives EU approval for the treatment of refractory partial-onset seizures in patients with TSC

January 31, 2017 Novartis has announced that the European Commission has approved Votubia® (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalization, are connected with tuberous sclerosis complex (TSC). Votubia is now the first approved pharmacologic therapy in all 28 member states of … Continue reading Novartis drug Votubia® receives EU approval for the treatment of refractory partial-onset seizures in patients with TSC

cellectis

Cellectis Gains FDA Approval for Testing New Gene-Edited Cancer Treatment

Feb 7, 2017 Cellectis, the Paris-based biotech, has received an Investigational New Drug, or IND, approval from the U.S. Food and Drug Administration (FDA) for conducting phase I clinical trials with UCART123, the gene-edited product candidate of the biotech, in patients with acute myeloid leukemia, or AML, and blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This is … Continue reading Cellectis Gains FDA Approval for Testing New Gene-Edited Cancer Treatment

Amgen Logo

Amgen Announces the Efficacy of Repatha® (Evolocumab) for Reducing The Risk Of Cardiovascular Events

Feb. 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal stroke, non-fatal myocardial infarction (MI), coronary revascularization or hospitalization for unstable angina) and … Continue reading Amgen Announces the Efficacy of Repatha® (Evolocumab) for Reducing The Risk Of Cardiovascular Events

Top Pharma News - IgeaHub

Top Pharma News – January 2017

Best Pharmaceutical News January 2017 by IgeaHub.com - All the Pharma Top News Stories, Analyses and Perspectives

johnson & johnson logo

Johnson & Johnson to Purchase Actelion for $30 Billion

Jan 26, 2017 Johnson & Johnson (J&J) has said that it is going to buy Swiss biotech Actelion Pharmaceuticals for $30 billion. The company also plans to spin out its research and development unit into a separate business. The deal is expected to close in mid-February. The companies said in a statement that J&J will pay $280 … Continue reading Johnson & Johnson to Purchase Actelion for $30 Billion